Cisplatin: mode of cytotoxic action and molecular basis of resistance
Z. Siddik
|
11 |
2003 |
11
2003
|
Activators and target genes of Rel/NF-κB transcription factors
H. Pahl
|
11 |
1999 |
11
1999
|
MAP kinase signalling pathways in cancer
A. Dhillon,
S. Hagan,
O. Rath,
W. Kolch
|
11 |
2007 |
11
2007
|
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. Roberts,
C. Der
|
11 |
2007 |
11
2007
|
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Anurag Singh,
J. Settleman
|
11 |
2010 |
11
2010
|
Molecular mechanisms of cisplatin resistance
20 auth.
L. Galluzzi,
L. Senovilla,
L. Senovilla,
L. Senovilla,
I. Vitale,
I. Vitale,
I. Vitale,
J. Michels,
J. Michels,
J. Michels,
...
I. Martins,
I. Martins,
I. Martins,
O. Kepp,
O. Kepp,
O. Kepp,
M. Castedo,
M. Castedo,
M. Castedo,
G. Kroemer
|
11 |
2012 |
11
2012
|
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.
8 auth.
T. Miyashita,
S. Krajewski,
M. Krajewska,
H. G. Wang,
H. Lin,
D. Liebermann,
...
B. Hoffman,
John Calvin Reed
|
11 |
1994 |
11
1994
|
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
S. Fulda,
K. Debatin
|
11 |
2006 |
11
2006
|
The Bcl-2 apoptotic switch in cancer development and therapy
Jerry M. Adams,
S. Cory
|
11 |
2007 |
11
2007
|
MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer
14 auth.
P. Ji,
S. Diederichs,
Wenbing Wang,
S. Böing,
R. Metzger,
P. Schneider,
N. Tidow,
B. Brandt,
H. Buerger,
Etmar Bulk,
...
Michael Thomas,
W. Berdel,
H. Serve,
C. Müller-Tidow
|
11 |
2003 |
11
2003
|
The tumor microenvironment and its role in promoting tumor growth
T. Whiteside
|
11 |
2008 |
11
2008
|
The p53 pathway: positive and negative feedback loops
S. Harris,
A. Levine
|
10 |
2005 |
10
2005
|
MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer
7 auth.
I. Asangani,
S. A. K. Rasheed,
D. Nikolova,
J. Leupold,
N. Colburn,
S. Post,
...
H. Allgayer
|
10 |
2008 |
10
2008
|
PI3K pathway alterations in cancer: variations on a theme
TL Yuan,
L. Cantley
|
10 |
2008 |
10
2008
|
STATs in oncogenesis
Tammy Bowman,
R. Garcia,
J. Turkson,
R. Jove
|
10 |
2000 |
10
2000
|
AP-1 in cell proliferation and survival
E. Shaulian,
M. Karin
|
10 |
2001 |
10
2001
|
Introduction to NF-κB: players, pathways, perspectives
T. Gilmore
|
10 |
2006 |
10
2006
|
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
G. Semenza
|
10 |
2010 |
10
2010
|
miR-21-mediated tumor growth
Sipahi Ml,
Shuomin Zhu,
Hailong Wu,
Zhaohui Lu,
Fangting Wu,
Y. Mo
|
10 |
2007 |
10
2007
|
Regulation of the G2/M transition by p53
W. Taylor,
G. Stark
|
10 |
2001 |
10
2001
|
